Green Tape provides back office services to Ebola ZMapp cocktail developer, Mapp

Green Tape Mapp

Sometimes, Providence steps in and changes the course of a life. 

 

 

Here’s hoping the path we’re on ultimately changes millions of lives. While Green Tape provides the back office services for small R&D businesses whose existence is based on federal contracts and grants, we’re thrilled to be part of an incredible story about making a difference in world healthcare.

One of our clients is making that difference. At first, it seemed more a dream, a vision. But that’s what businesses are built on, right? The principals’ passion was contagious; along with us, all the subcontractors saw the vision and bought into their dream.

Ebola outbreak is the worst in history

Earlier this year, tragedy struck: An Ebola outbreak began infecting Afrikaners. The cause of a deadly hemorrhagic fever, 60 percent of those who contract Ebola succumb to it. As of August 15, 2014, the World Health Organization reported that there have been 1,975 people had been diagnosed with Ebola and 1,060 had died – and the numbers continue to rise.

Dr. Sheik Humarr Khan was a leading Sierra Leone doctor who dedicated himself to caring for those with Ebola. He contracted the virus; when he died in late July, it seemed the world suddenly awoke and wanted to know what could be done. And when two American missionaries – one a doctor himself – contracted the virus in late July, their mission appealed to the U.S. government, which then stepped in to help its citizens.

Meanwhile, our client, Mapp Biopharmaceutical, Inc., had reached certain measures of success in its research and development on creating an Ebola antibody. When testing its antibody cocktail on monkeys that had the Ebola virus earlier this year, the triple antibody cocktail looked promising. While it was great news, the Zmapp cocktail wasn’t approved for clinical trials by the Food & Drug Administration.

Then something amazing happened

The FDA has a ‘compassionate care’ policy, which offers exceptions to its rigorous approval process. This policy allows treatment for someone who is suffering from a serious disease or condition for which there is no other alternative. Because there’s no cure for Ebola and the American missionaries’ health was failing fast, the federal government, at the mission Samaritan’s Purse’s request, allowed Mapp to deliver doses of ZMapp, its version of compassionate care, to the American missionaries.

Dr. Kent Brantly and missionary Nancy Writebol received Mapp’s triple cocktail antibody serum, ZMapp, which, so far, has been credited with helping them recover. Because no clinical trials have been performed on humans, any results the world is seeing are considered anecdotal. But the fact remains: They’re both still alive.

Near future: Vaccine will render Ebola powerless

‘Experts’ (and you have to wonder who the real ‘experts’ are, because Mapp’s principals aren’t talking – much, anyway) say that this recent Ebola outbreak could be the last. The expectation – or hope – is that before Ebola can rear its ugly head again, a vaccine will be readily and widely available, rendering it helpless against the advances of modern science.

Meanwhile, as you can imagine, we’re VERY busy serving this special client.